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Abstract: Around 3000 proteins are thought to bind zinc in vivo, which corresponds to ~10% of
the human proteome. Zinc plays a pivotal role as a structural, catalytic, and signaling component
that functions in numerous physiological processes. It is more widely used as a structural element
in proteins than any other transition metal ion, is a catalytic component of many enzymes, and
acts as a cellular signaling mediator. Thus, it is expected that zinc metabolism and homeostasis
have sophisticated regulation, and elucidating the underlying molecular basis of this is essential
to understanding zinc functions in cellular physiology and pathogenesis. In recent decades, an
increasing amount of evidence has uncovered critical roles of a number of proteins in zinc metabolism
and homeostasis through influxing, chelating, sequestrating, coordinating, releasing, and effluxing
zinc. Metallothioneins (MT) and Zrt- and Irt-like proteins (ZIP) and Zn transporters (ZnT) are
the proteins primarily involved in these processes, and their malfunction has been implicated in a
number of inherited diseases such as acrodermatitis enteropathica. The present review updates our
current understanding of the biological functions of MTs and ZIP and ZnT transporters from several
new perspectives.
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1. Introduction
Following the uptake of zinc by cells, it is distributed within the cytoplasm (50%), nucleus
(30%–40%), and cell membrane (10%) [1,2]. Cellular zinc is then available as four pools [2,3]. First,
it can bind tightly to metalloproteins as a structural component or to metalloenzymes as a cofactor;
Second, zinc binds metallothioneins (MTs) with a low affinity, which can occupy 5%–15% of the total
cellular zinc pool [4]; Third, it can be compartmentalized into intracellular organelles and vesicles for
zinc storage and as a supply for zinc-dependent proteins, which is mediated by zinc transporters [5,6].
As a result of the second and third functions, the fourth pool of cytosolic free zinc is maintained at a
very low concentration (pM–low nM levels) [7–9]. MTs and two zinc transporter families, Zrt- and
Irt-like proteins (ZIP, solute carrier 39A [SLC39A]) and Zn transporters (ZnT, SLC30A), play crucial
roles to maintain this cellular zinc homeostasis [2,3,10–12] (Figure 1). In this review, we focus on recent
progress to describe the physiological and biological functions of MTs and ZIP and ZnT transporters,
and to provide a better understanding of zinc biology.
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Figure 1. Cellular zinc homeostasis is controlled by the cooperative function of metallothioneins 
(MT) and Zrt- and Irt-like proteins (ZIP) and Zn transporters (ZnT). The mobilization of zinc into or 
out of the cytosol is directed by two zinc transporter families, ZIP and ZnT. In the cytosol, MTs bind 
zinc to reserve, buffer, and chelate. Zinc is compartmentalized into or out of intracellular organelles 
and vesicles by ZnT and ZIP transporters. Because of the binding of zinc to many different proteins, 
the free zinc ion concentration in the cytosol is estimated to be well below pM–low nM levels. 
2. Physiological and Cellular Functional Properties of Metallothioneins (MTs) 
2.1. MT Isoforms 
MTs are low-molecular-weight metal-binding proteins that lack disulfides and contain 
one-third cysteine residues. Human MTs have a total of 11 functional isoforms that can be divided 
into four classes, designated MT-1 to -4. These are encoded by eight active MT1 genes (MT1A, B, E, F, 
G, H, M, and X), and a single copy of MT2 (known as MT2A), MT3, and MT4. The human genome 
also contains five pseudo-MT1 genes derived from duplication and loss-of-function mutations of the 
original parental MT1. However, it is not clear whether the eight active MT1 genes have gained a 
new function. The mouse harbors single copies of MT1, 2, 3, and 4. A tree topology study suggested 
that two rounds of duplication have occurred in the MT family [13] (Figure 2). The neighbor-joining 
method of analysis of human MT genes using MEGA6 software (http://www.megasoftware.net/) 
(Figure 2) suggested that the ancestor of MT3/4 and MT1/2 diverged, after which MT3 and MT4  
seem to have separated. Conversely, the Bayesian and maximum likelihood methods of analysis [13] 
indicated that divergence of the MT4 and MT1/2/3 ancestor was the first step. In either case, 
following duplication of these genes, gain-of-function mutations are likely to have occurred in 
MT1/2, MT3, and MT4. MT-3 and -4 show a restricted cell type-specific expression pattern, with 
MT-3 being expressed mainly in the brain and MT-4 most abundant in certain epithelial tissues. 
These isoforms show specific roles in these tissues [14]. 
The ubiquitous MT isoforms MT-1 and -2 have been extensively investigated with regard to 
zinc metabolism. They are expressed in many cell types in various organs and tissues, as well as in 
most cultured cells, and their function is to maintain cellular zinc homeostasis and attenuate heavy 
metal-induced cytotoxicity by chelating these metals and lowering their intracellular concentrations. 
They also protect against several types of environmental stress through their radical scavenging 
properties [15]. 
It is unclear whether MT-1 and -2 have functional differences. Because of their similar amino 
acid sequences and inducibility in response to zinc and various stress conditions and compounds, 
most research studies of MT-1 and -2 have been done without separation. However, several lines of 
research show that the MT-1 and 2 isoforms have specific functions, which are summarized in  
Section 3.2. In the 1990s, two lines of MT1/2 double knockout (KO) mice were established to examine 
Figure 1. Cellular zi c homeostasis is controlled by the cooperativ functio f metallothioneins (MT)
and Zrt- and Irt-like proteins (ZIP) and Zn transporters (ZnT). The mobilization of zinc into or out of
the cytosol is directed by two zinc transporter families, ZIP and ZnT. In the cytosol, MTs bind zinc
to reserve, buffer, and chelate. Zinc is compartment lized into or out of i trac llular organelles and
vesicles by ZnT and ZIP transporters. Because of the binding of zinc to many different proteins, the
free zinc ion concentration in the cytosol is estimated to be well below pM–low nM levels.
2. Physiological and Cellular Functional Properties of Metallothioneins (MTs)
2.1. MT Isoforms
MTs are low-molecul r-weight metal-binding proteins t at lack disulfides and contain one-third
cysteine residues. Human MTs have a total of 11 functional isoforms that can be divided into four
classes, designated MT-1 to -4. These are encoded by eight active MT1 genes (MT1A, B, E, F, G,
H, M, and X), and a single copy of MT2 (known as T2A), MT3, and MT4. The human genome
also contains five pseudo-MT1 genes derived from duplication and loss-of-function mutations of the
original parenta MT1. However, it is not clear whether he eight active MT1 genes have gained a
new function. The mouse harbors single copies of MT1, 2, 3, and 4. A tree topology study suggested
that two rounds of duplication have ccurr d n the MT family [13] (Figure 2). The neighbor-joining
method of analysis of human MT genes using MEGA6 software (http://www.megasoftware.net/)
(Figure 2) suggested that the ancestor of MT3/4 d MT1/2 diverged, after which MT3 and MT4
seem to have separated. Conversely, the Bayesian and maximum likelihood methods of analysis [13]
indicated that divergence of the MT4 and MT1/2/3 ancestor was the first step. In either case, following
duplication of these ge es, gain-of-function mutations are likely to have occurred in MT1/2, MT3, and
MT4. MT-3 and -4 show a restricted cell type-specific expression pattern, with MT-3 being expressed
mainly in the brain and MT-4 most abu dant in certain epithelial tissues. These isoforms show specific
roles in these tissues [14].
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only in the prot ction against m tal  [16–19], oxidative stress [20], and carci oge s [21], but also in 
immune reactions and obesi y (Table 1). MT1/2 KO mic  hav  a high sensiti ity to lipopolysaccharide 
(LPS) and LPS/D-galactosamine, o represent an acute hepatic failur  model [22,23]. Howev r,  
t e protective mechanisms are unclear. MT1/2 KO mice also showed increased H licobacter pylori  
(H. pylori)-induced gastric erosive lesion  [24]. These lesions are associated with production of 
reactive oxy en species (ROS) from infiltrated macrophages and neutrophils. ROS sc venging 
activity of MT ight b  involved in the sen itizatio . A report detailing a decrea e in interleukin 
(IL)-4 production in MT1/2 KO mice, which is mediat d by FcεRI-induced calcineurin (CaN)/nuclear 
factor of activated T-cell (NFAT) signaling p thway, suggests that th  MT-depende t control of zinc 
homeostasis regulates IL-4 production in basophil granulocytes [25]. I terestingly, zinc transporter 
KO mice such s Zip10 KO als  showe  an altered immune response [26,27]. We describe th  KO 
ph notyp  of zinc transporters in Sections 5.2 and 5.3. 
 
Figure 2. Phylogenetic tree of MT genes. The tree was constructed using coding sequences from 
NCBI RefSeq and the neighbor-joining method using MEGA6 software. 
As shown in Table 1, two strains of MT1/2 KO mice exist. The first is 129SvCPJ [16], while the 
second was originally developed on a mixed genetic background of OLA129 and C57BL/6 strains [17] 
then backcrossed with C57BL/6J Jcl. The KO phenotype shown in Table 1 might be strain-specific. 
Other phenotypes, such as high-fat diet-induced obesity [28] and a shortened lifespan [29], appeared 
through unknown mechanisms. 
Table 1. Knockout (KO) phenotypes of MT1/2. 
Phenotype Strain References
Metal binding 
Increased sensitivity to heavy metal toxicity 129/Sv, C57BL/6 [16,17,19] 
Increased sensitivity to zinc deficiency and excess C57BL/6 [18] 
Decreased FcεRI-induced IL-4 production, which is mediated by calcineurin 
(CaN)/nuclear factor of activated T-cell (NFAT) signaling, in basophil granulocytes 
C57BL/6 [25] 
Reduced survival in Cu/Zn-superoxide dismutase (SOD1)-mutated (G93A) mice, which is 
a familial mouse model of amyotrophic lateral sclerosis (ALS) 
129/Sv [30] 
Reactive oxygen species (ROS) scavenging 
Increased sensitivity to X-irradiation-induced bone marrow injury C57BL/6 [20] 
Increased chemical and radiation-induced carcinogenesis C57BL/6 [21] 




Increased sensitivity to lipopolysaccharide (LPS)/D-galactosamine-induced lethality 129/Sv [22] 
Increased coagulatory and fibrinolytic disturbance and multiple organ damage 
induced by LPS 
C57BL/6 [23] 
High-fat-diet-induced obesity, increased plasma leptin and leptin mRNA in the white 
adipose tissue when fed the high-fat-die (a leptin-resistant state) 
129/Sv [28] 
Shorten the lifespan, exhibiting signs of weight loss, hunchbacked spines, lackluster fur 
and an absence of vigor in male living beyond the mean lifespan 
129/Sv [29] 
Figure 2. Phylogenetic tree of MT genes. The tree was constructed using coding sequences from NCBI
RefSeq and the neighbor-joining method using MEGA6 software.
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The ubiquitous MT isoforms MT-1 and -2 have been extensively investigated with regard to
zinc metabolism. They are expressed in many cell types in various organs and tissues, as well as in
most cultured cells, and their function is to maintain cellular zinc homeostasis and attenuate heavy
metal-induced cytotoxicity by chelating these metals and lowering their intracellular concentrations.
They also protect against several types of environmental stress through their radical scavenging
properties [15].
It is unclear whether MT-1 and -2 have functional differences. Because of their similar amino
acid sequences and inducibility in response to zinc and various stress conditions and compounds,
most research studies of MT-1 and -2 have been done without separation. However, several lines
of research show that the MT-1 and 2 isoforms have specific functions, which are summarized in
Section 3.2. In the 1990s, two lines of MT1/2 double knockout (KO) mice were established to examine
the functional properties of MT-1 and -2 [16,17]. MT1/2 KO mice were viable and reproduced normally
when reared under standard laboratory conditions. The function of MT1/2 was shown not only in
the protection against metals [16–19], oxidative stress [20], and carcinogens [21], but also in immune
reactions and obesity (Table 1). MT1/2 KO mice have a high sensitivity to lipopolysaccharide (LPS) and
LPS/D-galactosamine, so represent an acute hepatic failure model [22,23]. However, the protective
mechanisms are unclear. MT1/2 KO mice also showed increased Helicobacter pylori (H. pylori)-induced
gastric erosive lesions [24]. These lesions are associated with production of reactive oxygen species
(ROS) from infiltrated macrophages and neutrophils. ROS scavenging activity of MT might be
involved in the sensitization. A report detailing a decrease in interleukin (IL)-4 production in MT1/2
KO mice, which is mediated by FcεRI-induced calcineurin (CaN)/nuclear factor of activated T-cell
(NFAT) signaling pathway, suggests that the MT-dependent control of zinc homeostasis regulates IL-4
production in basophil granulocytes [25]. Interestingly, zinc transporter KO mice such as Zip10 KO
also showed an altered immune response [26,27]. We describe the KO phenotype of zinc transporters
in Sections 5.2 and 5.3.
Table 1. Knockout (KO) phenotypes of MT1/2.
Phenotype Strain References
Metal binding
Increased sensitivity to heavy metal toxicity 129/Sv, C57BL/6 [16,17,19]
Increased sensitivity to zinc deficiency and excess C57BL/6 [18]
Decreased FcεRI-induced IL-4 production, which is mediated by calcineurin
(CaN)/nuclear factor of activated T-cell (NFAT) signaling, in basophil granulocytes C57BL/6 [25]
Reduced survival in Cu/Zn-superoxide dismutase (SOD1)-mutated (G93A) mice,
which is a familial mouse model of amyotrophic lateral sclerosis (ALS) 129/Sv [30]
Reactive oxygen species (ROS) scavenging
Increased sensitivity to X-irradiation-induced bone marrow injury C57BL/6 [20]
Increased chemical and radiation-induced carcinogenesis C57BL/6 [21]
Increased Helicobacter pylori (H. pylori)-induced gastric erosive lesions with infiltration
of leukocytes C57BL/6 [24]
Unknown mechanisms
Increased sensitivity to lipopolysaccharide (LPS)/D-galactosamine-induced lethality 129/Sv [22]
Increased coagulatory and fibrinolytic disturbance and multiple organ damage
induced by LPS C57BL/6 [23]
High-fat-diet-induced obesity, increased plasma leptin and leptin mRNA in the white
adipose tissue when fed the high-fat-die (a leptin-resistant state) 129/Sv [28]
Shorten the lifespan, exhibiting signs of weight loss, hunchbacked spines, lackluster
fur and an absence of vigor in male living beyond the mean lifespan 129/Sv [29]
As shown in Table 1, two strains of MT1/2 KO mice exist. The first is 129SvCPJ [16], while the
second was originally developed on a mixed genetic background of OLA129 and C57BL/6 strains [17]
then backcrossed with C57BL/6J Jcl. The KO phenotype shown in Table 1 might be strain-specific.
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Other phenotypes, such as high-fat diet-induced obesity [28] and a shortened lifespan [29], appeared
through unknown mechanisms.
Mutations in the Cu/Zn-superoxide dismutase (SOD1) gene cause one form of familial
amyotrophic lateral sclerosis (ALS), a progressive disorder of motor neurons leading to death. MT1/2
deficiency in mouse model of ALS involving mutated SOD1 (G93A SOD1) shows a reduction in
survival compared with G93A SOD1 mice [30]. SOD1 is an enzyme that binds zinc, and abnormalities
in this binding have been implicated in disease pathogenesis [31]. This study indicated that MT acts as
a zinc chaperone for apo-SOD1. We discuss the possibility of MT being a zinc chaperone in more detail
in Sections 3.1 and 6.
2.2. The Zinc-Responsive Transcription Factor MTF-1
MT1/2 transcription is regulated by the metal response element-binding transcription factor-1
(MTF-1), which is a zinc finger transcription factor that regulates metal-responsive gene expression [32]
(Figure 3). In MTF-1 KO cells, MT1/2 genes are silent. MTF-1 is an essential factor for basal and heavy
metal-induced MT1/2 expression. It possesses six Cys2His2 zinc fingers and three transcriptional
activation domains, namely an acidic domain, a proline-rich region, and a serine/threonine-rich region.
A simple metalloregulatory model suggests that MTF-1 has a low intrinsic binding affinity for zinc,
and only binds zinc under zinc excess conditions. Specific zinc fingers in MTF-1 were shown to have
zinc-binding affinities in the nM to sub-µM range [33], while canonical Cys2His2 zinc fingers typically
bind zinc with higher affinity (10´9–10´12 M). Because zinc affinities of all six fingers are similar
in MTF-1 (within ~10–50-fold of each other), zinc-sensing by MTF-1 is suggested to occur within
a 100-fold or less range of accessible zinc concentration [34].
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increases MT transcription. In MT-repressed cells such as lymphosarcoma cells, and cancer cells, the 
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(MBD) are involved in the suppression. The epigenetic mechanism is described in Section 4.2. Ac, 
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Figure 3. Expression regulation of MT gene expression. (A) Schematic representation of human
metal response element-binding transcription factor-1 (MTF-1). The regions of the six-zinc fingers
(F1–F6), acidic, proline-rich, and serine/threonine-rich domains are indicated by boxes and amino
acid numbers; (B) Proposed molecular mechanisms in MT transcription in response to i creases of
intracellular fr e zinc. In generic cells, MTF-1 recruits the histone acetyltransferase p300 and increases
MT transcription. In MT-repressed cells such as lymphosarcoma cells, and cancer cells, the promoter is
highly methylated. DNA methyltransferase (DNMT) and methyl CpG binding proteins (MBD) are
involved in the suppression. The epigenetic mechanism is described in Section 4.2. Ac, acetyl group;
Me, methyl group; blue circle with two lines, nucleosome.
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MTF-1 also regulates the zinc-responsive transcription of ZnT1 and ZnT2 [35,36] and represses the
expression of Zip10 [37,38], indicating that it plays an important role in zinc homeostasis. The tumor
suppressor phosphatase and tensin homolog modulates the MTF-1-mediated expression of ZnT1 and
MT [39], suggesting a relationship between tumorigenesis and zinc homeostasis. Protein phosphatase
2A has also been reported to be involved in MT induction [40]. In addition to MTF-1, a recent finding
revealed that another zinc finger transcription factor, ZNF658, is involved in the regulation of zinc
transporter expression [41]. Thus, ZNF658 may cooperatively function as a transcriptional regulator
with MTF-1 in the controlled cellular response to zinc availability.
3. Structural and Biochemical Functions of MTs
3.1. MT Functions in Physiological and Cellular Zinc Homeostasis
MT was first identified as a protein containing heavy metals such as cadmium and zinc [42].
MTs intracellularly bind these metals and lower their concentration at critical sites. A role for MT
in cellular zinc homeostasis was predicted before being experimentally confirmed [4,14,43]. In one
study, mouse fibroblasts were adapted to extreme zinc deprivation (<0.06 µM zinc vs. sub-µM levels
in normal medium) by increasing MT-1 mRNA expression through MT1 amplification without MT
protein accumulation. Apo-MT chelates zinc from the environment and increases intracellular zinc.
When zinc levels were insufficient to stabilize the MT protein, the MT was rapidly proteolyzed. Zinc
is then released by MT degradation, so the intracellular zinc concentration was kept constant. In
contrast, when cells expressing MT3 were deprived of zinc, cell proliferation was arrested and MT-3
protein levels persisted. MT1/2 were shown to scavenge extracellular zinc, not to compete with
essential zinc-requiring proteins, and to be degraded, while MT3 was shown to compete for zinc and
to exacerbate the zinc deficiency [44].
MTs can also function as a “zinc buffer” through their low-affinity binding, providing labile zinc
for use by target proteins/enzymes when zinc is limited [45,46]. Specifically, several zinc-requiring
apoenzymes can be reactivated by the transfer of zinc from zinc-saturated MT, which binds seven
zinc ions. One study proposed the model that zinc-saturated Zn7-MT and Zn6-MT are the primary
zinc-donating species for apo-carbonic anhydrase, a zinc-requiring enzyme [47]. In particular, MT is
a source of zinc ions under conditions of redox signaling through the modifications of zinc-thiolate
coordination environments [48,49], which contribute to the functions of zinc in cellular signaling [50].
It has also been reported that apo-MT removes zinc from the zinc finger transcription factors Sp1 and
transcription factor IIIA in vitro, and eliminates their DNA-binding ability [51,52]. Thus, MT appears
to act as a chaperone for zinc proteins/enzymes. This role involves the transfer of zinc from MT to
proteins/enzymes via ligand exchange in zinc-mediated protein–protein interactions in the absence
of freely released zinc ions, which is known as “the associative mechanism” [46,53,54] as seen in
copper metabolism [55–57]. In this similar metabolism, several copper chaperones play critical roles in
transferring cytosolic copper to target proteins/enzymes [55–57].
3.2. Specific Functions of MT-1 and -2 Isoforms
Although MT-1 and 2 have been largely studied together, the specific functions of these proteins
have only begun to be elucidated [58,59]. For instance, comparing the stability of rat zinc-saturated
MT-1 and MT-2, MT-2 was shown to degrade more slowly than MT-1 [58]. More recently, zinc-saturated
MT-2 was found not to exist under normal physiological conditions [60], although it is unclear whether
stability differs among zinc-unsaturated isoforms.
Several studies of MT single nucleotide polymorphisms (SNPs) showed that MT2A but not MT1
SNPs are associated with an increased cancer risk [61–63] (Table 2). However, because the basal level
of MT2A expression appears to be 5–10 times higher than that of MT1X, this association might be
caused by MT2A expression levels. MT isoform-specific gene regulation mechanisms have also been
reported. As an example, vascular endothelial growth factor was shown to induce human MT1G, but
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not MT2A, by regulating the E2F transcription factor [64], while bovine MT1A and 1E, but not MT2A,
are induced through the Keap1-Nrf2 system [65]. Such isoform-specific functions may result from
isoform-specific expression mechanisms.
However, MT isoform-specific linkage has also been reported. MT2A interacts with
homeobox-containing 1 (HMBOX1) in human umbilical vascular endothelial cells to increase
intracellular free zinc concentrations [66]. Knockdown of MT2A decreases intracellular free
zinc, while treatment with a zinc chelator inhibited HMBOX1-regulated apoptosis and promoted
HMBOX1-regulated autophagy. The interaction between MT1X, Akt, and tongue cancer
resistance-associated protein 1 (TCRP1) in oral squamous cell carcinoma [67] was also reported.
In this report, MT1X knockdown increased cisplatin-induced apoptosis. Although these MT isoforms
might have specific functions, their amino acid sequences have a high level of homology. Therefore,
further investigations are needed to clarify the mechanisms of isoform-specific function.
Table 2. Specific MT1/2 isoform functions.
Isoform Isoform Specific Function Findings Ref.
MT1A Increase risk of lung cancer Single nucleotide polymorphisms (SNPs) (rs7196890) [68]
MT1A,
1G Regulate myeloid differentiation
Negatively regulated by PU.1 in leukemia cells
(in microarray analysis)
Inhibition of retinoic acid-induced differentiation by
MT1G overexpression.
[69,70]
MT1X Mediate cisplatin-induced apoptosis
Interacts with Akt and tongue cancer
resistance-associated protein 1 (TCRP1) in oral
squamous cell carcinoma (in microarray analysis) [67]
Increased sensitivity to cisplatin through activation
of phosphatidylinositol-3-kinase
(PI3K)/Akt/nuclear factor-κB (NF-κB) signaling
pathway by knockdown of MT1X with TCRP1
MT2A Regulate autophagy and apoptosis
Inhibition of intracellular free zinc elevation by
knockdown of MT2A
[66]Interacts with homeobox containing 1 (HMBOX1)
(in yeast two-hybrid assay), overexpression of which
increases intracellular free zinc
Inhibition of anti-apoptosis and pro-autophagy
effects of HMBOX1 by zinc chelator,
N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine
(TPEN)
MT2A Increase risk of prostate cancer SNPs (rs28366003) [61,62]
MT2A Increase risk of ductal breast cancer SNPs (rs28366003) [63]
4. Novel Regulation of MT Expression
4.1. SNPs in the MT Promoter
As described in Section 2.2, MT1/2 expression is regulated by the transcription factor MTF-1
(Figure 3). In MTF-1 KO cells, MT1/2 genes are silent, and therefore MTF-1 is essential for basal
and heavy metal-induced MT1/2 expression, while other transcription factors are also involved in
the expression [71]. For example, signal transducer and activator of transcription 3 (STAT3) and
glucocorticoid receptor (GR) transcription factors are required for MT expression in response to
immune response mediation by IL-6. The SNP-dependent decrease of MT2A expression was also
reported in a Japanese study [72] in which 17.6% of 119 individuals had an AÑ G SNP (A/G: 16.8%,
G/G: 0.8%) in the MT2A promoter near the TATA box (rs28366003). A reporter gene assay using
HEK293 cells showed that replacement of A by G reduced MT2A expression to 30%–70% after zinc and
cadmium treatment. In separate studies, Yoshida et al. reported increased cadmium levels in the renal
cortex of individuals with (group A) and without (group B) MT accumulation [73,74]. Because MT is
a cytoprotective factor against cadmium, group B individuals might be expected to be more sensitive to
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cadmium toxicity than group A. Although the genetic background of these groups was not examined,
group B might be expected to have A/G or G/G genotypes. As shown in Table 2, this SNP is also
positively associated with lung, prostate and ductal breast cancer [61–63,68]. Another possibility for
the difference between groups A and B is the involvement of epigenetic regulation of MT expression.
4.2. Epigenetic Regulation of MT Expression
MT expression is also regulated through epigenetic mechanisms. Although MT1/2 is ubiquitously
expressed, some cell lines do not express MTs (Figure 3). Jacob et al. reported that the suppression
of MT1 expression was caused by promoter-specific DNA methylation [75,76]. Moreover, inhibitors
of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) synergistically activate its
expression [77]. In MT1/2-expressing cells, the HDAC p300 is involved in a zinc-induced
MTF-1-containing complex [78]. MTF-1 deletion mutant analysis revealed that this complex plays an
essential role in the activation of MT1 transcription. Furthermore, zinc rapidly and locally disrupts the
MT1 promoter chromatin structure by nucleosome removal. Binding of MTF-1 to the MT1 promoter
was required to initiate histone exclusion, but was not necessary to maintain this exclusion, at least in
the short term [79]. IL-2 transcription has been reported to occur earlier in zinc re-stimulated mouse
T cells than at the first stimulation [80], and this is thought to reflect histone exclusion from the MT1
promoter, which acts as a memory of the first zinc exposure.
The epigenetic mechanisms involved in MT transcription are not fully understood, although
their disruption modifies MT transcription. Chromatin remodeling complexes such as the
SWI–SNF complex are not required for cadmium-induced mouse MT1 transcription [81], while
prenatal zinc deficiency affects cadmium-induced mouse MT2 transcription through epigenetic
mechanisms [82]. Hexavalent chromium (Cr6+), a heavy metal known for over 100 years to be a human
carcinogen, inhibits mouse MT1 transcription by modifying the transcription potential of p300 [83].
Cross-linking of HDAC1–DNMT1 complexes to chromatin might be involved in the inhibition of MT
transcription [77,84,85]. These epigenetic mechanisms might influence the biochemical functions
of MT.
5. Cellular Zinc Homeostasis Involving ZIP and ZnT Zinc Transporters
5.1. Zrt- and Irt-Like Proteins (ZIP) and Zn Transporters (ZnT) Transporters
In addition to the chelating and releasing by MTs, mobilization of zinc across biological
membranes is important to maintain cellular and subcellular zinc homeostasis. Although zinc ions
can cross biological membranes through various calcium channels, ZIP and ZnT transporter family
proteins play crucial roles as transport routes [86,87] (Figure 4). ZIP transporters mobilize zinc from
the extracellular space or intracellular organelles to the cytosol, while ZnT transporters function in
zinc efflux and compartmentalization as cation diffusion proteins.
A total of 14 ZIP and nine ZnT transporter genes are encoded in mammalian genomes.
Each of the zinc transporters shows a tissue-specific, developmental, stimulus-responsive expression
pattern, and specific cellular and subcellular localization. Both transporters display specific
changes in protein stability and cellular localization in response to various stimuli including zinc
deficiency or excess [2,10–12]. Recent studies have indicated that epigenetic expression control
occurs in a number of ZIP and ZnT transporters, as seen for MT genes (Section 4.1) [88,89].
Moreover, micro RNA-mediated expression control has also been revealed to control cellular zinc
homeostasis [90,91]. Molecular information about both zinc transporters, including expression
regulation at the protein level, discrimination of substrate metal, and transport mechanism, is
extensively reviewed elsewhere [2,12,92], so is not covered here.
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5.2. Overview of ZIP Transporter Knockout Animals and Human Diseases
Zip1, Zip2, and Zip3 KO mice are more likely to produce abnormal embryos when dietary zinc is
deficient [93–96]. Zip3 KO mice also show zinc retention in the secreted milk pool [97], while Zip1 and
Zip3 double KO mice reduce seizure-induced CA1 neurodegeneration [98], suggesting the involvement
of ZIP3 in zinc reuptake from milk secreted from mammary glands and the involvement of ZIP1 and
ZIP3 in neural degeneration induced by zinc entry. ZIP4 has been identified as the gene responsible
for a rare autosomal-recessive inherited zinc deficiency, acrodermatitis enteropathica (AE) [99,100]. AE
is caused by impaired intestinal absorption of zinc, and is characterized by eczematous dermatitis,
diarrhea and alopecia [101,102]. The importance of ZIP4 in zinc absorption and intestinal integrity
was also confirmed by intestine-specific conditional Zip4 KO mice [103] because complete Zip4 KO
mice are embryonically unviable [104].
Missense and nonsense mutations of ZIP5 have been shown to be associated with nonsyndromic
high myopia [105], although this has not been investigated using Zip5 KO mice. However,
complete and tissue-specific Zip5 KO mice were used to show the participation of ZIP5 in the
control of zinc excretion [106]. ZIP8 SNPs (such as rs13107325, resulting in A391T substitution)
were associated with the circulation of high-density lipoprotein cholesterol [107] and blood
pressure [108]. Hypomorphic Zip8 mice show utero and neonatal lethality because of multiple
organ hypoplasia [109], while chondrocyte-specific conditional Zip8 KO mice suppress surgically
induced osteoarthritis pathogenesis [110], indicating that ZIP8 induces the cartilage breakdown
of osteoarthritis [110]. Recently, loss-of-function ZIP8 mutations have been associated with
human diseases including intellectual disability, cerebellar atrophy, severe infantile spasms with
hypsarrhythmia, disproportionate dwarfism, developmental delay and hypotonia, strabismus, and
cranial asymmetry [111,112].
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B-cell-specific conditional Zip10 KO mice show splenoatrophy with reduced peripheral B cell
numbers and diminished immunoglobulin levels, indicating the involvement of ZIP10 in anti-apoptotic
signaling in early B-cell survival [26]. Both T-cell-dependent and independent immune responses
are attenuated in the mature B cells of Zip10 KO mice, revealing its importance in the modulation of
B-cell receptor signaling [27]. Recent analysis using ZIP12 KO rats showed that ZIP12 regulates the
pulmonary vascular response to chronic hypoxia [113], while ZIP13 mutations have been shown to
cause the spondylocheiro dysplastic form of Ehlers–Danlos syndrome (SCD-EDS) [114,115], which
is characterized by hard and connective tissue abnormalities. Zip13 KO mice show delayed growth,
and skeletal and connective tissue abnormalities, which are phenotypes similar to those of SCD-EDS
patients [115]. Finally, Zip14 KO mice exhibit dwarfism, impaired skeletogenesis [116], hypoglycemia,
greater body fat, and higher insulin levels than wild-type [117]. Moreover, hepatocyte proliferation is
decreased in Zip14 KO mice during liver regeneration [118]. The study using Zip14-KO mice revealed
its involvement in the uptake of plasma non-transferrin bound iron by the liver and pancreas, and
thus possibly in iron overload in hereditary hemochromatosis [119].
5.3. Overview of ZnT Transporter Knockout Animals and Human Diseases
KO mice of ZnT transporters also indicate their crucial roles in zinc-related pathophysiology.
Znt1 KO mice are embryonically unviable from an early stage because of the impaired zinc transfer
from the mother [120]. ZnT2 has been identified as the gene responsible for transient neonatal zinc
deficiency (TNZD), which is caused by low zinc levels in breast milk [121–125]. The symptoms are
similar to AE, but TNZD only develops in breast-fed infants, and does not reoccur after weaning. ZnT2
KO mice showed the importance of ZnT2 during lactation and mammary gland development [126],
while ZnT3 KO mice show age-dependent defects in learning and memory such as spatial working
and fear [127–129]. They also lack synaptic zinc [130] and display differences in protein and gene
expression important in neurotransmission [127], suggesting modulation functions of ZnT3 in synaptic
transmission and plasticity. Moreover, loss of ZnT3 function increases the risk of febrile seizures in
humans [131].
A spontaneous Znt4 mutant mouse produces milk with reduced zinc levels, so-called lethal milk
because pups nursed by these dams die before weaning [132]. Recently, the Znt4 mutant mouse
was shown to have defects in mammary gland secretion and hallmarks of precocious involution
during lactation [133]. Znt5 KO mice display poor growth, osteopenia, and male-specific sudden
cardiac death [134], and also show cytokine production defects in mast cells, which is mediated by
the high-affinity immunoglobulin E receptor [135]. Znt7 KO mice show poor growth, decreased
adiposity, and mild zinc deficiency, while males also have high-fat diet induced-insulin resistance and
glucose intolerance [136]. Nonsynonymous ZnT8 SNPs (rs13266634, resulting in R325W substitution)
are known to increase the risk of type 2 diabetes [137–140], which is attributed to the lower zinc
transport activity of the risk allele although the precise molecular mechanism of this requires
further investigation because Znt8 KO mice phenotypes have been variable in sex and genetic
background [2,141]. Nevertheless, all Znt8 KO mice have defects in the formation of zinc–insulin
crystals [142–146]. Contrary to these findings, a recent finding showed that the single
nucleotide variants causing the truncation of ZnT8 protect against type 2 diabetes in heterozygous
individuals [147]. This discrepancy also needs further investigation from the viewpoint of ZnT8 zinc
transport activity. The rs13266634 SNP is also a determinant of humoral autoreactivity to ZnT8 [148].
Finally, homozygous ZnT10 mutations are involved in Parkinsonism, which is characterized by
hypermanganesemia, hepatic cirrhosis, polycythemia, and dystonia [149,150]. Recent molecular
analysis indicates that ZnT10 is functional in the detoxification of cellular manganese [151].
We briefly summarize information about ZIP and ZnT transporter mutations in human genetic
diseases in Table 3. Moreover, many SNPs have been reported in ZIP and ZnT transporter genes that
are suggested to be associated with human diseases. This information is summarized elsewhere [2,152].
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Table 3. Zinc transporter mutations reported to be involved in inherited diseases.
Gene Disease MIM No. Clinical Features Pattern of Inheritance References
SLC39A4/ZIP4 Acrodermatitis enteropathica (AE) 201100
Eczematous dermatitis on the perioral, perianal, and areas,
alopecia, diarrhea, growth retardation because of decreased
zinc absorption, Ameliorated with zinc supplementation.
Homozygous, Compound
heterozygous, Dominant negative [99–101,153,154]
SLC39A5/ZIP5 Nonsymptomatic high myopia 615946 Refractive error, tigroid and focal atrophy of choroid. Heterozygous [105]
SLC39A8/ZIP8
Cerebellar Atrophy Syndrome, a type II
congenital disorder of glycosylation
(CDG)
-
Intellectual disability, cerebellar atrophy, cranial asymmetry,




SLC39A13/ZIP13 spondylocheiro dysplastic Ehlers-Danlossyndrome (SCD-EDS) 612350
Postnatal growth retardation, skeletal and connective tissue
abnormalities, finger contractures, joint hypermobility,
protruding eyes with bluish sclera, decreased hydroxyl
collagen levels.
Homozygous [114,115]
SLC30A2/ZnT2 Transient neonatal zinc deficiency(TNZD) 608118
Erosive dermatitis around the mouth, genital region, neck,
and fingers, diarrhea, hair loss, alopecia, Ameliorated with
zinc supplementation to infants.
Dominant negative, Heterozygous,
Compound heterozygous [121–125]
SLC30A3/ZnT3 Increased risk of febrile seizures - Potentially a prelude to more severe epilepsy. Heterozygous [131]
SLC30A10/ZnT10 Hypermanganesemia, syndrome ofhepatic cirrhosis, dystonia, polycythemia 613280
Dysarthria, hypertonia, fine tremor, bradykinesia, spastic
paraparesis, Improved by metal chelation therapy. Homozygous [149,150]
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6. Cooperative Functions of MT and ZnT Transporters in Cellular Events
6.1. Cooperative Regulation of MT and ZnT Transporters Controls Cytosolic Zinc Homeostasis
The maintenance mechanisms of cellular zinc homeostasis are known as “zinc buffering” and
“zinc muffling” [60,155]. This buffering mechanism is important to maintain a zinc ion concentration
in the cytosol in the pM range and is achieved by cytosolic zinc-binding proteins including MTs. The
muffling mechanism is functional under non-steady conditions, in which transient changes in zinc ion
concentrations in the cytosol are modulated by zinc-binding proteins such as MTs and zinc transporters
through moving zinc ions into subcellular compartments or out of cells [60,155]. When free zinc ion
concentrations in the cytosol are sufficiently high, MTF-1 induces the transcription of MT-1 and -2 and
several ZnT transporters, and their cooperative expression contributes to the maintenance of cellular
zinc homeostasis [32,34–36]. Thus, the cooperative regulation of MT and ZnT transporters is essential
to control cellular zinc homeostasis over a variety of zinc levels.
6.2. Cooperative Regulation of MT and ZnT Transporters for the Activation of Zinc-Dependent Ectoenzymes
In addition to the maintenance of cellular zinc homeostasis, the cooperative functions of MTs
and zinc transporters likely contribute to various biological events. However, the molecular evidence
for this is limited. We recently studied the activation process of a zinc-requiring ectoenzyme, tissue
non-specific alkaline phosphatase (TNAP), to more thoroughly investigate this [156]. The activation
of TNAP needs ZnT5–ZnT6 heterodimers and ZnT7 homodimers of the early secretory pathway as
a zinc entry route into the lumen of the pathway [157–159]. Unexpectedly, cells lacking MT, ZnT1,
and ZnT4 (ZnT1´{´MT´{´ZnT4´{´) also show significantly reduced TNAP activity, in spite of
normal operation of ZnT5–ZnT6 heterodimers and ZnT7 homodimers and increased cytosolic zinc
levels [123,156]. Interestingly, the impairment of TNAP activation in ZnT1´{´MT´{´ZnT4´{´ cells is
reversed by excess zinc supplementation [156], strongly suggesting that the transfer of cytosolic zinc
to ZnT5–ZnT6 heterodimers and ZnT7 homodimers may be facilitated under the cooperative control
of ZnT1, MT, and ZnT4 (Figure 5).
The phenotypes of ZnT1´{´MT´{´ZnT4´{´ cells are somewhat similar to those of cytosolic
copper chaperone Atox1-deficient cells, in which intracellular copper levels are increased [160,161]
but the activity of secretory cuproenzymes is significantly reduced [162,163]. However, the
impairment of cuproenzyme activation is recovered by excess copper supplementation to the
cells [162,163]. Atox1 plays a crucial role as a copper chaperone in the facilitated transfer
of cytosolic copper to copper-transporting ATPases (ATP7A and ATP7B) to activate secretory
cuproenzymes in the trans-Golgi network [55,56,164]. Considering the phenotypic analogies between
ZnT1´{´MT´{´ZnT4´{´ cells and Atox1-deficient cells, it is interesting to hypothesize the presence
of cytosolic zinc chaperone proteins, which conduct the facilitated transfer of cytosolic zinc to
ZnT5–ZnT6 heterodimers and ZnT7 homodimers. Both ZnT1 and ZnT4 are membrane proteins,
while MT is a cytosolic protein. Thus, MT may be functional as a cytosolic chaperone through its
cooperative operation with ZnT1 and ZnT4, although there is no experimental evidence as yet for
this. This type of zinc chaperone protein has been speculated based on the molecular modeling
of bacterial ZnT homologs, which may have an Atox1-like structure, and appears to dock to the
intracellular cavity between transmembrane domains and carboxyl-terminal cytoplasmic domains of
ZnT transporters [165].
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Figure 5. Cooperative function of MT, ZnT1, and ZnT4 in the activation of zinc-requiring ectoenzymes.
The facilitated transfer of cytosolic zinc to ZnT5–ZnT6 heterodimers and ZnT7 homodimers may
function under cooperative control of ZnT1, MT, and ZnT4 (left). ZnT1MTZnT4 KO cells exhibit
significantly reduced TNAP activity (left), which is reminiscent of the phenotypes of cytosolic copper
chaperone Atox1-deficient cells (right). Atox1 plays a crucial role as a copper chaperone in transferring
cytosolic copper to two copper-transporting P-type ATPases, ATP7A and ATP7B, located in the
trans-Golgi network (TGN). This therefore contributes to the activation of copper-requiring ectoenzymes
(cuproenzymes). Considering the high level of analogy between ZnT1MTZnT4 KO and Atox1-deficient
cells, a putative zinc chaperone under the cooperative control of ZnT1, MT, and ZnT4 is hypothesized
to play a crucial role in facilitating the transfer of cytosolic zinc to ZnT5–ZnT6 heterodimers and ZnT7
homodimers (not shown) located in the early secretory pathway (ESP). This then contributes to the
proper activation of zinc-requiring ectoenzymes such as TNAP (left).
7. Perspectives
The field of zinc metabolism and homeostasis has undergone a dramatic expansion indicating in
recent decades, which has revealed that zinc plays important roles in a variety of biological processes.
However, the molecular basis underlying these mechanisms has only relatively recently been identified.
Many questions remain to be answered with respect to zinc metabolism and its involvement in
the divergent array of physiological and pathophysiological processes. These include how zinc
ions are sensed and recognized by proteins including MTF-1, MT, and ZIP and ZnT transporters.
Moreover, how do MT and ZIP and ZnT transporters operate correctly during zinc transfer to target
proteins/enzymes through zinc release via ligand-centered reactions in zinc-thiolate coordination in
MT, or zinc mobilization across the biological membranes by ZIP and ZnT transporters? How are
these processes activated and controlled in terms of both timing and location? In connection with
this, is a zinc chaperone operative in cellular zinc metabolism? Furthermore, how are MT, ZIP and
ZnT transporter gene expression controlled epigenetically? Finally, why are so many MTs present in
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humans and do they have an isoform-specific function? Answers to these questions should provide an
important direction for future work on zinc as well as an understanding of the roles of zinc in health
and disease.
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AE acrodermatitis enteropathica
ALS amyotrophic lateral sclerosis












MBD methyl CpG binding protein
MTF-1 metal response element-binding transcription factor-1
NFAT nuclear factor of activated T-cell
NF-κB nuclear factor-κB
PI3K phosphatidylinositol-3-kinase




STAT3 signal transducer and activator of transcription
TCRP1 tongue cancer resistance-associated protein 1
TGN trans-Golgi network
TNAP tissue non-specific alkaline phosphatase
TNZD transient neonatal zinc deficiency
TPEN N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine
ZIP Zrt- and Irt-like protein
ZnT Zn transporter
ZNF zinc finger transcription factor
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